Abstract
Tuberculosis (TB) is a notifiable infectious disease. Globally, 20% patients of TB are contributed by India. The World Health Organization (WHO) and the Revised National Tuberculosis Control Program (RNTCP) formulates guidelines for management of TB. There have been advances in various aspects of TB. This review enumerates the progress aiming the therapeutic aspects for TB. The WHO revised definitions in TB in 2013. With the availability of rapid diagnostics and WHO goal of universal access to the same; the diagnostic approach was modified. The RNTCP shifted therapy administration for drug sensitive TB (DS-TB) from thrice weekly to daily regimen in 2017. The WHO updated the drug resistant TB (DR-TB) guidelines in 2016. Bedaquiline and delamanid got enlisted as add-on drugs in the revised classification. In the end, we discuss various pipelines in development of TB.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
